Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-99220732 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event.
A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (\>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities.
| Arm | Type | Description |
|---|---|---|
| JNJ-99220732 (Part 1 and Part 2) | EXPERIMENTAL | Participants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first. |
| Name | Type | Description |
|---|---|---|
| JNJ-99220732 | DRUG | JNJ-99220732 will be administered intravenously. |
Inclusion criteria: \- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (\>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specif...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, IMGN632, ABBV-744 |
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Luspatercept, BMS-986158, Fedratinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics Inc | KPTIQ | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Axatilimab, Ruxolitinib, INCB160058, INCB057643, INCA033989 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Revumenib |